巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-10-14
2022-07-25
2022-07-23
2021-11-21
2021-06-23
2022-07-24
2023-02-19
2022-12-21
2021-09-03
2023-08-18
2021-06-20
2021-04-15
